Abstract
Hereditary spinocerebellar ataxia (SCA) is a devastating, incurable disease. Stem-cell-based therapies represent new promise for clinical research in neurology. The objectives of this study were to assess the feasibility, efficacy, and potential toxicity of human umbilical cord mesenchymal stem cells (UCMSCs) therapy in patients with SCA. Sixteen genomically diagnosed SCA patients were enrolled and received intravenous and intrathecal infusion of UCMSCs. Clinical, laboratory, and radiographic evaluations were conducted to assess the safety of UCMSC therapy. Efficacy was evaluated by the Berg Balance Scale (BBS) and International Cooperative Ataxia Rating Scale (ICARS) scores. Among the 16 cases, there were no serious transplant-related adverse events happened in 12 months follow-up. The majority of patients showed improved BBS and ICARS scores continuing for at least 6 months which indicated UCMSC therapy could alleviate SCA symptoms. This study suggested that UCMSC transplantation was safe and might delay the progression of SCA. This may represent a new therapeutic strategy for SCA and other genetic neurological diseases.
Keywords: Berg Balance Scale, Efficacy, International Cooperative Ataxia Rating Scale, Safety, Spinocerebellar Ataxia, Umbilical Cord Mesenchymal Stem Cell
Current Neurovascular Research
Title:Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy in Hereditary Spinocerebellar Ataxia
Volume: 10 Issue: 1
Author(s): Jia-Li Jin, Zhuo Liu, Zhen-Juan Lu, De-Ning Guan, Chong Wang, Zhi-Bin Chen, Jun Zhang, Wei-Yun Zhang, Jia-Yong Wu and Yun Xu
Affiliation:
Keywords: Berg Balance Scale, Efficacy, International Cooperative Ataxia Rating Scale, Safety, Spinocerebellar Ataxia, Umbilical Cord Mesenchymal Stem Cell
Abstract: Hereditary spinocerebellar ataxia (SCA) is a devastating, incurable disease. Stem-cell-based therapies represent new promise for clinical research in neurology. The objectives of this study were to assess the feasibility, efficacy, and potential toxicity of human umbilical cord mesenchymal stem cells (UCMSCs) therapy in patients with SCA. Sixteen genomically diagnosed SCA patients were enrolled and received intravenous and intrathecal infusion of UCMSCs. Clinical, laboratory, and radiographic evaluations were conducted to assess the safety of UCMSC therapy. Efficacy was evaluated by the Berg Balance Scale (BBS) and International Cooperative Ataxia Rating Scale (ICARS) scores. Among the 16 cases, there were no serious transplant-related adverse events happened in 12 months follow-up. The majority of patients showed improved BBS and ICARS scores continuing for at least 6 months which indicated UCMSC therapy could alleviate SCA symptoms. This study suggested that UCMSC transplantation was safe and might delay the progression of SCA. This may represent a new therapeutic strategy for SCA and other genetic neurological diseases.
Export Options
About this article
Cite this article as:
Jin Jia-Li, Liu Zhuo, Lu Zhen-Juan, Guan De-Ning, Wang Chong, Chen Zhi-Bin, Zhang Jun, Zhang Wei-Yun, Wu Jia-Yong and Xu Yun, Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy in Hereditary Spinocerebellar Ataxia, Current Neurovascular Research 2013; 10 (1) . https://dx.doi.org/10.2174/1567202611310010003
DOI https://dx.doi.org/10.2174/1567202611310010003 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Transcranial Magnetic Stimulation to Understand the Pathophysiology and Treatment of Substance Use Disorders
Current Drug Abuse Reviews Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology Promising Pharmacological, Molecular and Cellular Treatments of Autoimmune Hepatitis
Current Pharmaceutical Design Mechanisms of Anorexia Cancer Cachexia Syndrome and Potential Benefits of Traditional Medicine and Natural Herbs
Current Pharmaceutical Biotechnology Perspective on Acetylcholinesterase: A Potential Target for Alzheimer’s Disease Intervention
Current Enzyme Inhibition Understanding the Global Problem of Drug Addiction is a Challenge for IDARS Scientists
Current Neuropharmacology The Immunocompromised Host: Immune Alterations in Splenectomized Patients and Clinical Implications
Current Pharmaceutical Design Non-allowed Pharmacologically Active Substances in Physical and Sexual Performance Enhancing Products
Current Neuropharmacology Visible Light Assisted Hantzsch Reaction: Synthesis of Polycyclic Dihydropyridines
Letters in Organic Chemistry Food Fortification with Omega-3 Fatty Acids; Microencapsulation as an Addition Method
Current Nutrition & Food Science Psychoimmunological Analysis of Cancer Patients: Correlation with the Prognosis
Current Aging Science Interferon Therapy for Malignant Solid Tumors
Current Drug Therapy Heat Shock Protein 90 – a Potential Target in the Treatment of Human Acute Myelogenous Leukemia
Current Cancer Drug Targets Commentary: Stephen William Hawking (8 January 1942 – 14 March 2018)
CNS & Neurological Disorders - Drug Targets Using Bioinformatics Techniques for Gene Identification in Drug Discovery and Development
Current Drug Metabolism Major Mental Disorders and Violence: A Critical Update
Current Psychiatry Reviews Oxidative Stress in Schizophrenia
Current Neuropharmacology A Random Forest-Induced Distance-Based Measure of Physiologic al Dysregulation
Current Aging Science Fibromyalgia Syndrome: Which Antidepressant Drug Should We Choose
Current Pharmaceutical Design Regulation of Innate Immune Responses in the Central Nervous System
CNS & Neurological Disorders - Drug Targets